Association between serum cytokine profiles and clearance or persistence of high-risk human papillomavirus infection: A prospective study

International Journal of Gynecological Cancer

Volumn 20, Issue 6, 2010, Pages 1011-1016

  Hong, Jin Hwa ^a   Kim, Mi Kyung ^b   Lee, Ho ^c   Kim, Tae Jin ^c   Kwak, San Ha ^a   Song, Seung Hun ^a   Lee, Jae Kwan ^a  

^a Korea University College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

^c Catholic Kwandong University   (South Korea)

Author keywords

Human papillomavirus; Interferon ; Interleukin 10; Interleukin 6; Tumor necrosis factor

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA; BIOLOGICAL MARKER; CYTOKINE;

ADULT; AGED; ARTICLE; CORRELATIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; METABOLIC CLEARANCE RATE; ORAL CONTRACEPTION; PAPILLOMAVIRUS INFECTION; PARITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SMOKING; WART VIRUS; ANALYSIS OF VARIANCE; BLOOD; CERVICAL INTRAEPITHELIAL NEOPLASIA; INCIDENCE; ISOLATION AND PURIFICATION; KOREA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PRECANCER; PREDICTIVE VALUE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOKINES; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INCIDENCE; KOREA; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 77956792704     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181e513e5     Document Type: Article

References (35)

1. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-265. (Pubitemid 34293391)
2. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst. 1995;87:796-802.
3. Evander M, Edlund K, Gustafsson A, et al. Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis. 1995;171: 1026-1030.
4. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423-428.
5. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327:1272-1278.
6. Kyo S, Inoue M, Hayasaka N, et al. Regulation of early gene expression of human papillomavirus type 16 by inflammatory cytokines. Virology. 1994;200:130-139.
7. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342-350.
8. Spellberg B, Edwards JE Jr. Type 1/type 2 immunity in infectious diseases. Clin Infect Dis. 2001;32:76-102.
9. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol. 1994;12:227-257.
10. Wu TC, Kurman RJ. Analysis of cytokine profiles in patients with human papillomavirus-associated neoplasms. J Natl Cancer Inst. 1997;89:185-186.
11. Aggarwal BB. Signaling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745-756.
12. Arany I, Grattendick KG, Tyring SK. Interleukin-10 induces transcription of the early promoter of human papillomavirus type 16 (HPV 16) through the 5-segment of the upstream regulatory region (URR). Antiviral Res. 2002;55:331-339.
13. Farzaneh F, Roberts S, Mandal D, et al. The IL-10 1082G polymorphism is associated with clearance of HPV infection. B JOG. 2006;113:961-964.
14. Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol. 2001;8:209-220.
15. Tjiong MY, van der Vange N, ten Kate FJ, et al. Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer. Gynecol Oncol. 1999;73:285-291.
16. Wei LH, Kuo ML, Chen CA, et al. Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol. 2001;82:49-56.
17. Castellsague X, Munoz N. Chapter 3: cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003;31:20-28.
18. Garcia-Pineres AJ, Hildesheim A, Herrero R, et al. Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. Cancer Res. 2006;66:11070-11076.
19. Sharma A, Rajappa M, Saxena A, et al. Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix. Int J Gynecol Cancer. 2007;17:879-885.
20. Clerici M, Merola M, Ferrario E, et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst. 1997;89:245-250.
21. Mindiola R, Caulejas D, Nunez-Troconis J, et al. Increased number of IL-2, IL-2 receptor and IL-10 positive cells in premalignant lesions of the cervix. Invest Clin. 2008;49:533-545.
22. Song SH, Lee JK, Lee NW, et al. Interferon-γ (IFN-γ): a possible prognostic marker for clearance of high-risk human papillomavirus (HPV). Gynecol Oncol. 2007;108:543-548.
23. Woodworth CD, Lichti U, Simpson S, et al. Leukoregulin and gamma-interferon inhibit human papillomavirus type 16 gene transcription in human papillomavirus immortalized human cervical cells. Cancer Res. 1992;52:456-463.
24. Welters MJ, de Jong A, van den Eeden SJ, et al. Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res. 2003;63:636-641.
25. Niwa Y, Akamatsu H, Niwa H, et al. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res. 2001;7:285-289.
26. Lebrecht A, Hefler L, Tempfer C, et al. Serum cytokine concentrations in patients with cervical cancer: interleukin-4, interferon-gamma, and monocyte chemoattractant protein-1: to the editor. Gynecol Oncol. 2001;83:170-171.
27. Gaiotti D, Chung J, Iglesias M, et al. Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent pathway. Mol Carcinog. 2000;27:97-109.
28. Bais AG, Beckmann I, Lindemans J, et al. A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol. 2005;58:1096-1100.
29. van Snick J. Interleukin-6: an overview. Ann Rev Immunol. 1990;8:253-278.
30. Iglesias M, Plowman GD, Woodworth CD. Interleukin-6 and interleukin-6 soluble receptor regulate proliferation of normal, human papillomavirus- immortalized, and carcinoma-derived cervical cells in vitro. Am J Pathol. 1995;146:944-952.
31. Matsuda M, Salazar F, Petersson M, et al. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med. 1994;180:2371-2376.
32. Jacobs N, Giannini SL, Doyen J, et al. Inverse modulation of IL-10 and IL-12 in the blood of women with preneoplastic lesions of the uterine cervix. Clin Exp Immunol. 1998;111: 219-224.
33. Lee DW, Kim YT, Kim SW, et al. Expression of interleukin-5 and tumor necrosis factor alpha in cervical carcinoma. Clin Vaccine Immunol. 2009;16:959-961.
34. Azar KK, Tani M, Yasuda H, et al. Increased secretion patterns of interleukin-10 and tumor necrosis factor-alpha in cervical squamous intraepithelial lesions. Hum Pathol. 2004;35:1376-1384.
35. Castle PE, Hildesheim A, Bowman FP, et al. Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels. J Clin Immunol. 2002;22:23-27.